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Alzheimer’s disease (AD), the most common 
neurodegenerative disorder, is character-
ized by progressive memory and cognitive 
impairment and the cerebral accumula-
tion of extracellular amyloid plaques and 
intraneuronal neuroﬁ  brillary  tangles.  A 
principal neuropathological ﬁ  nding in AD 
subjects is cortical atrophy associated with 
degeneration of neurites, decreased den-
dritic spine density and frank neuronal loss 
(Terry et al., 1991; Knobloch and Mansuy, 
2008). Although the speciﬁ  c molecular initi-
ators of the AD process remain unknown in 
most patients, biochemical studies indicate 
that the severity of cognitive impairment in 
AD correlates more strongly with the corti-
cal levels of soluble amyloid β- protein  (Aβ 
assemblies than with the burden of insoluble 
amyloid plaques (Lue et al., 1999; McLean 
et al., 1999; Shankar et al., 2008). Extensive 
experimental work on hippocampal plastic-
ity has indicated that the induction of long-
term synaptic depression (LTD) results in 
decreased dendritic spine volume or out-
right elimination of spines (Matsuzaki et al., 
2004; Nägerl et al., 2004; Zhou et al., 2004), 
changes which may parallel molecular and 
structural aspects of synaptic failure in AD. 
Therefore, understanding how Aβ impairs 
hippocampal synaptic function at the 
molecular level could enable the develop-
ment of speciﬁ  c neuroprotective therapies 
for AD.
Studies from numerous laboratories have 
now established that soluble Aβ oligomers 
can inhibit long-term potentiation (LTP), 
or the strengthening of synapses, in the 
  hippocampus. But heretofore, only a few 
studies have examined the effects of Aβ on the 
induction of LTD, and those few have yielded 
inconsistent results. For example, synthetic 
Aβ peptides were reported to potently enable 
the induction of LTD in CA1 in an NMDAR-
dependent manner in vivo (Kim et al., 2001; 
Cheng et al., 2009), whereas other studies 
found no effect on LTD in slices (Wang et al., 
2002, 2004; Raymond et al., 2003). To address 
this problem, we recently extracted buffer-
soluble Aβ oligomers directly from the brains 
of typical AD patients and demonstrated 
that these species can facilitate LTD induc-
tion in hippocampal slices of wild-type mice 
(Shankar et al., 2008). While the induction 
of both LTP and LTD requires glutamatergic 
transmission, the direction in which synaptic 
strength is modulated by the speciﬁ  c class 
of glutamate receptor that is activated, the 
kinetics of cytosolic calcium concentration, 
and the initiation of intracellular signaling 
cascades. Speciﬁ  cally, we found that LTD 
induction was facilitated by pathophysiologi-
cally relevant low concentrations of soluble 
Aβ oligomers through activation of either 
NMDA receptors or metabotropic glutamate 
receptors (mGluRs), depending on the elec-
trical stimulation protocol used to induce the 
LTD (Li et al., 2009). Given that several prior 
studies, including our own, have already 
shown that Aβ has little or no effect on pre-
synaptic neurotransmitter release probability 
(e.g., Townsend et al., 2006; Shankar et al., 
2008; Cheng et al., 2009), we hypothesized 
that the Aβ oligomers alter synaptic gluta-
mate concentration by disrupting glutamate 
transport mechanisms. In the current study, 
we report that pharmacologically blocking 
glutamate uptake closely recapitulates the 
effects of Aβ on LTD induction, suggest-
ing that Aβ oligomers bias towards synapse 
weakening in part through such a mecha-
nism (Li et al., 2009).
A growing number of reports indicate 
that glutamate transporters are disturbed 
in AD (Masliah et al., 1996). The levels of 
transporters such as GLAST/EAAT1 and 
GLT-1/EAAT2 are reduced in postmor-
tem AD brain tissue and in APP transgenic 
mice (Maragakis et  al., 2004; Jacob et  al., 
2007). Synthetic Aβ (at supraphysiological 
concentrations) has been shown to inhibit 
glutamate uptake in cultured neurons and 
astrocytes (Harris et  al., 1996; Harkany 
et al., 2000; Fernández-Tomé et al., 2004) 
and in oocytes (Gu et al., 2004). Although 
most glutamate transporters are located on 
astrocytes, reduced neuronal expression of 
EAAT1 was also suggested to be an early 
marker of neuronal dysfunction in AD, pre-
ceding or occurring on a similar timeline to 
the expression of hyper-phosphorylated tau 
protein in the same neurons of AD brains 
(Scott et al., 2002). Interestingly, it was dem-
onstrated recently that detergent insoluble 
EAAC1/EAAT3 transporters accumulate 
aberrantly in hippocampus in AD subjects 
(Duerson et al., 2009). Taken together, these 
various reports suggest that neuronal and/or 
glial glutamate uptake may be interrupted 
in AD.
Glutamate transporters play the impor-
tant role of regulating concentrations of 
glutamate in the extracellular space, keep-
ing it at low levels. Without normal activ-
ity of glutamate transporters, glutamate 
would accumulate to cytotoxic levels and 
could contribute to progressive neuronal 
loss in AD (Pomara et al., 1992; Harkany 
et al., 2000). Early AD studies focused on 
frank Aβ-enhanced excitotoxicity medi-
ated through glutamate receptors, espe-
cially NMDA receptors (Greenamyre and 
Young, 1989; Mattson et  al., 1992; Hynd 
et al.,  2004). However, the perturbations 
in extracellular glutamate levels result-
ing from altered transport kinetics could 
even be responsible for the more subtle 
ultrastructural alterations noted in AD, such 
as dendritic spine loss. In vivo microdialysis 
recently revealed that soluble Aβ oligom-
ers secreted by APP-transfected cells, when 
microinjected into wild-type rat brain, can Li et al.  Aβ oligomers impair synaptic plasticity
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signiﬁ  cantly increase the hippocampal  levels 
of extracellular glutamate but not GABA or 
aspartate (O’Shea et al., 2008). Inhibition 
of glutamate uptake by the pharmacologi-
cal agent TBOA has been shown to increase 
spontaneous epileptiform discharges, and 
this increased excitability can be blocked 
by the NMDA antagonist, AP5 (Campbell 
and Hablitz, 2004). In our current study, 
we found that the effects of Aβ oligomers 
in facilitating LTD in hippocampal slices 
were very similar to those of TBOA (Li 
et al.,  2009). Interestingly, Aβ accumula-
tion in vivo has been found to signiﬁ  cantly 
increase spontaneous nonconvulsive sei-
zure activity in cortical and hippocampal 
networks in APP transgenic mice (Palop 
et al., 2007). In the context of these vari-
ous studies, our new ﬁ  ndings that soluble 
Aβ oligomers can facilitate the induction of 
LTD through both an mGluR pathway (300-
pulse stimulation protocol) and a NMDAR 
pathway (900-pulse stimulation protocol) 
and that this LTD induction is mimicked by 
the effect of TBOA suggest that a common 
upstream element, the neuronal glutamate 
transporter, is misregulated by diffusible Aβ 
oligomers.
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